-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Increases By 2,468.9%
Short Interest in Q BioMed Inc. (OTCMKTS:QBIO) Increases By 2,468.9%
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 156,700 shares, a growth of 2,468.9% from the November 30th total of 6,100 shares. Based on an average daily trading volume, of 745,200 shares, the short-interest ratio is currently 0.2 days.
Q BioMed Price Performance
Shares of QBIO traded down $0.00 during mid-day trading on Wednesday, hitting $0.01. 642,508 shares of the company's stock were exchanged, compared to its average volume of 443,292. Q BioMed has a 52 week low of $0.01 and a 52 week high of $0.58. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.03.
Get Q BioMed alerts:Q BioMed (OTCMKTS:QBIO – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.
About Q BioMed
(Get Rating)Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
See Also
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 156,700 shares, a growth of 2,468.9% from the November 30th total of 6,100 shares. Based on an average daily trading volume, of 745,200 shares, the short-interest ratio is currently 0.2 days.
Q BioMed Inc.(场外交易代码:QBIO-GET Rating)是12月份空头股数大幅增长的接受者。截至12月15日,空头股数共有156,700股,比11月30日的6,100股增长了2,468.9%。以日均成交量745,200股计算,目前短息比为0.2天。
Q BioMed Price Performance
Q BioMed性价比
Shares of QBIO traded down $0.00 during mid-day trading on Wednesday, hitting $0.01. 642,508 shares of the company's stock were exchanged, compared to its average volume of 443,292. Q BioMed has a 52 week low of $0.01 and a 52 week high of $0.58. The company has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.03.
周三午盘,QBIO股价下跌0.00美元,触及0.01美元。该公司股票成交量为642,508股,而其平均成交量为443,292股。Q BioMed的52周低点为0.01美元,52周高位为0.58美元。该公司的50日简单移动均线切入位在0.02美元,200日简单移动均线切入位在0.03美元。
Q BioMed (OTCMKTS:QBIO – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $0.03 million during the quarter.
Q BioMed(OTCMKTS:QBIO-GET Rating)最近一次发布收益报告是在11月3日星期四。该公司公布了本季度每股收益(0.03美元)。该公司本季度的收入为30万美元。
About Q BioMed
关于Q BioMed
Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.
Q BioMed Inc.是一家生物医学加速和开发公司,专注于许可、收购和向生命科学和医疗保健公司提供资源。该公司提供氯化锶SR89和美沙酮,这是一种治疗转移性骨癌疼痛的放射性药物。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
- The Top Three Stocks Analysts Say To Buy
- Can Dick's Sporting Goods Stock Score Another Win In Q4?
- Yum! Brands Looks Tasty in 2023
- Why Did Immutep Ltd Stock Soar Recently?
- 3 Industrial Stocks to Help Build Your 2023 Watchlist
- 免费获取有关Q BioMed(QBIO)的StockNews.com研究报告
- 分析师认为最值得买入的三只股票
- Dick‘s Sports Goods Stock能否在第四季度再获胜利?
- 好吃!品牌在2023年看起来很美味
- 为什么Immutep公司的股票最近飙升了?
- 帮助你建立2023年观察名单的3只工业股票
Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.
接受Q BioMed Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Q BioMed和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧